{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Clinical response for neutrophils was assessed as the number of participants achieving a hematological improvement - neutrophils (HI-N). Response was defined as an absolute increase in neutrophils \\> 0.5 × 10\\^9/L that was also an increase of ≥ 100%.","groups":[{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 100 mg once daily.","id":"OG000","title":"Enasidenib Mesylat 100 mg"},{"description":"Participants in this dose-escalation cohort self-administered enasidenib mesylate orally at a dose of 200 mg once daily.","id":"OG001","title":"Enasidenib Mesylat 200 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"8 weeks","title":"Clinical Response: Hematological Improvement - Neutrophils (HI-N)","type":"SECONDARY","unitOfMeasure":"Participants"}